ArticlemedRxiv : the preprint server for health sciences2025
Personalized circulating tumor DNA dynamics predict survival and response to immune checkpoint blockade in recurrent/metastatic head and neck cancer.
Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
16 authors.
Funding
Abstract
Background: Recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) is an aggressive cancer with a median overall survival of only 12 months. Existing biomarkers have limited ability to predict treatment response or survival, exposing many patients to the potential toxicity of treatment without certain clinical benefit. Circulating tumor DNA (ctDNA) has emerged as a non-invasive, real-time biomarker that could address these challenges. Methods: We analyzed 137 plasma samples from 16 patients with R/M HNSCC undergoing immune checkpoint blockade (ICB)-based therapy. A tumor-informed, highly sensitive next-generation sequencing liquid biopsy assay (RaDaR, NeoGenomics Laboratories, Inc.) was applied to track ctDNA changes at baseline and throughout treatment. Univariable and multivariable analyses were used to assess the association between ctDNA negativity and key clinical outcomes: disease control (best objective response of stable disease, partial response, or complete response), three-year overall survival (OS), and three-year progression-free survival (PFS). We also assessed a machine learning model to predict disease progression based on ctDNA dynamics. Results: Multivariable analysis revealed that ctDNA negativity during treatment was significantly associated with improved disease control (OR 21.7, 95% CI 1.86-754.88, p=0.0317), three-year OS (HR 0.04, 95% CI 0.00-0.47, p=0.0103), and three-year PFS (HR 0.03, 95% CI 0.00-0.37, p=0.0057). The machine learning model predicted disease progression with 88% accuracy (AUC 0.89). Conclusion: Serial ctDNA monitoring predicted disease control, survival, and progression in patients with R/M HNSCC receiving treatment with ICB, suggesting that incorporation of ctDNA into clinical practice could enhance treatment decision-making for clinicians and improve patient outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.